摘要目的:探讨放射性 125I粒子植入治疗头颈部恶性肿瘤的近期治疗效果。 方法:本研究为回顾性研究，选取2014年9月至2019年3月北部战区总医院放射治疗科收治的29例接受放射性 125I粒子植入治疗头颈部肿瘤复发的患者(共32个病灶)，男24例，女5例，年龄(61.69±11.10)岁，年龄范围为41~82岁。在CT辅助下植入 125I粒子，观察植入治疗后的治疗效果和不良反应情况。 结果:125I粒子植入后2个月，局部有效率为53.1%(17/32)，局部控制率为100%(32/32)。植入后4个月，局部有效率为71.9%(23/32)，局部控制率为100%(32/32)。植入后6个月，局部有效率为81.3%(26/32)，局部控制率为93.8%(30/32)。1例鼻咽癌患者行术后剂量验证时发现粒子移位，1例口腔癌患者术后肿瘤消退后出现面部塌陷，1例下咽癌患者术后10个月出现自发性气胸，但无法评估其与粒子植入治疗相关性。 结论:放射性 125I粒子植入治疗头颈部恶性肿瘤近期治疗效果较好，对患者造成的创伤和风险小。

abstractsObjective:To investigate the short-term therapeutic effect of radioactive 125I seed implantation in the treatment of head and neck malignant tumor. Methods:This study was a retrospective study, a total of 29 patients who received radioactive 125I seed implantation for recurrent head and neck tumors(a total of 32 lesions)were admitted to the department of Radiotherapy, the General Hospital of Northern Theater Command from September 2014 to March 2019. 125I seeds were implanted with the help of CT to observe the therapeutic effect and adverse reactions after implantation. Results:Two months after 125I seed implantation, the local effective rate was 53.1%(17/32), and the local control rate was 100%(32/32). Four months after implantation, the local effective rate was 71.9%(23/32), and the local control rate was 100%(32/32). Six months after implantation, the local effective rate was 81.3%(26/32)and the local control rate was 93.8%(30/32). Particle displacement was found in one patient with nasopharyngeal cancer during postoperative dose verification, facial collapse occurred in 1 patient with oral cancer after postoperative tumor regression, and spontaneous pneumothorax occurred in one patient with hypopharyngeal cancer ten months after surgery, but its correlation with particle implantation could not be evaluated. Conclusions:Radioactive 125I seed implantation for the treatment of head and neck malignant tumors is convenient and feasible in terms of short-term efficacy and safety, with little trauma and risk to patients.It provides a very beneficial treatment for patients with advanced head and neck malignant tumors after treatment.